

1 **Title:** Global Menstrual Cycle Symptomatology

2 Alessandra J Ainsworth, MD ¹

3 Kimberly Peven, PhD²

4 Ryan Bamford, MSc²

5 Liudmila Zhaunova, PhD²

6 Rodion Salimgaraev, MD²

7 Carley Prentice, BA²

8 Aidan Wickham, PhD²

9 Jazz Croft, PhD²

10 Sonia Ponzio, PhD^{2,3}

11 Samir Babayev, MD ¹

12 ¹ Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology and
13 Infertility, Mayo Clinic, Rochester, Minnesota

14 ² Flo Health UK Limited, London, United Kingdom

15 ³ University College London, Institute of Health Informatics

16

17 Address Correspondence to: Samir Babayev, MD

18 Mayo Clinic

19 200 First Street SW

20 Rochester, MN 55905

21 (507) 284-2511

22 Babayev.samir@mayo.edu

23 Short Title: Global Menstrual Symptoms

24 **Financial Disclosure:** Kimberly Peven: Flo Health UK Limited (Employment), Ryan Bamford:
25 Flo Health UK Limited (Employment), Liudmila Zhaunova: Flo Health UK Limited
26 (Employment, ownership interest includes stock, stock options), Rodion Salingaraev: Flo
27 Health UK Limited (Employment, ownership interest includes stock, stock options), Carley
28 Prentice: Flo Health UK Limited (Employment), Aidan Wickham: Flo Health UK Limited
29 (Employment), Jazz Croft: Flo Health UK Limited (Employment), Sonia Ponzo: Flo Health UK
30 Limited (Employment, ownership interest includes stock, stock options). Other authors did not
31 report any potential conflicts of interest.

32

33 Title: Global Menstrual Cycle Symptomatology

34

35 Precis: Menstrual symptoms include both positive and negative physical and mood symptoms

36 and differ by age.

37

38 Abstract

39 **Objective:** To investigate symptomatology throughout the menstrual cycle, including the
40 frequency of symptoms reported for each phase of the cycle and the relationship between
41 symptoms and individual characteristics.

42 **Methods:** This study included self-reported cycle information and symptoms during ovulatory
43 menstrual cycles in mobile application users. Symptom frequency was described overall, by
44 phase, and by day. Relationships between symptoms and individual characteristics (age, body
45 mass index) were tested with logistic regression.

46 **Results:** 224,676 unique users and 498,126 unique cycles were included in the analysis. Somatic
47 symptoms were most frequently reported, logged in 85.3% of cycles. Of total symptoms logged,
48 somatic, gastrointestinal, and negative mood symptoms were most prevalent in the late luteal and
49 bleeding days, while positive mood and discharge were most common in the fertile window.
50 Symptom experience differed by age.

51 **Conclusions:** Menstrual cycle-related symptoms are very common and vary throughout the cycle
52 phases. While most women report negative symptoms including pain, bloating, and negative
53 mood, women also report positive symptoms such as energetic and happy mood. Self-reported
54 data from cycle tracking and health apps can improve our understanding of the prevalence and
55 variability of menstrual-related symptoms.

56

57 Funding Source: Flo Health UK Limited

58 **Introduction:**

59 Although a shared experience by women and people who menstruate throughout the world,
60 menstruation represents an area of health often ignored and misunderstood by both patients and
61 health care providers. While many individuals experience menstruation without significant
62 symptoms, others endure pain and many other somatic, gastrointestinal, and mood symptoms
63 which vary throughout the cycle. Dysmenorrhea affects 45-95% of menstruating individuals with
64 wide variation due to differing definitions of the condition¹. Compared with pain-free phases of
65 their cycles, those suffering from dysmenorrhea experience reduced quality of life, poor mood,
66 and decreased sleep during menstruation¹. Gastrointestinal symptoms also vary throughout the
67 menstrual cycle, with one-third of women experiencing symptoms during menstruation^{2,3}.
68 Additionally, irritability and mood swings can affect 22-40% of women, more often before
69 menstruation⁴. As it relates to symptom co-occurrence, individuals with mood symptoms like
70 depression and anxiety are more likely to experience multiple gastrointestinal symptoms both
71 before and during menstruation⁵. Despite improved standardization in terminology and
72 increasing prioritization of women's health issues, these symptoms are underreported⁶⁻⁸.
73 Importantly, menstrual symptoms may present a significant impairment to productivity and
74 quality of life⁹.

75 A recent review highlighted challenges in the field of menstrual health research¹⁰. These
76 challenges include how and from whom data is collected, the impact of normalization of
77 symptoms and stigma regarding menstrual disorders, lack of standardized assessment tools, and
78 differing cultural perceptions of this physiologic process¹⁰⁻¹³. Previous studies of symptom
79 prevalence and variation throughout the menstrual cycle have included surveys based on recall or
80 small prospective studies^{4,5}. Multiple approaches to improve our understanding of patient

81 symptoms and population norms of menstrual cycle symptoms, both normal and abnormal, are
82 required to best address current gaps in knowledge. The emerging availability of mobile
83 applications (apps) and user-reported data is one such approach that allows for ‘digital
84 epidemiology’^{14–16}. For example, reported cycle characteristics of more than 600,000 menstrual
85 cycles recorded by a mobile app found a mean luteal phase length of 12.4 ± 2 days¹⁷. This data
86 represents population norms and differs from the classical teaching of a conserved 14-day luteal
87 phase¹⁷.

88 In this study, through app user-reported data, we aim to report a population-based
89 assessment of symptomatology throughout the menstrual cycle. Specific objectives include
90 describing the frequency of symptoms reported in each phase of the menstrual cycle and
91 evaluation of how symptoms may be associated with personal characteristics.

92 **Methods:**

93 This cohort study includes active users of the Flo app between January 1, 2018, and April 1,
94 2022. Users aged 18-45, not pregnant, and actively involved in the app (reporting at least six
95 menstrual cycles) were included. Menstrual cycles between 21-40 days, menstrual bleeding
96 between 1-10 days, follicular and luteal phase lengths of at least five days each, and positive
97 ovulation predictor kit use were used to define ‘normal’ menstrual cycles.

98 Cycle dates and phases were calculated based user provided data. The start of a new
99 menstrual cycle was defined as the first day of bleeding. Mid-follicular phase was defined as the
100 day after the last day of menstrual bleeding until the start of the fertile window (Figure 1). An
101 individual with less than five days between end of menstrual bleeding and day of ovulation had
102 no defined mid-follicular phase. The fertile window was calculated as the five days preceding

103 ovulation and day of ovulation estimated as the day following a user reported positive ovulation
104 predictor kit. The luteal phase was split evenly in half and described as the early luteal phase and
105 the late luteal phase.

106 Symptoms were self-reported and associated with the phase of the menstrual cycle as
107 defined above. We classified symptoms into five groups: somatic (cramps, tender breasts,
108 headache, fatigue, backache, acne), gastrointestinal (bloating, nausea, diarrhea, cravings,
109 constipation), positive mood (happy, high sex drive, energetic), negative mood (mood swings,
110 anxious, depressed, insomnia, stress, obsessive thoughts), and discharge (creamy, egg white,
111 sticky, watery). Users could record as many symptoms in each category as desired each day.

112 Individual characteristics were matched to each cycle. Age at the time of the cycle was
113 based on the user's birthdate and cycle dates. Height and weight were optionally entered into the
114 app by users and used to calculate body mass index (BMI). A user's country was assigned based
115 on phone settings at app installation. Where country at app installation was unavailable, country
116 phone settings at last login was used. Country prevalence of symptoms was evaluated only when
117 100 users or more were included.

118 **Statistical Methods**

119 Using a cycle-level unit of analysis, we employed descriptive statistics to describe cycle
120 length and symptoms experienced overall and by phase. For cycles with a length of 25-30 days,
121 we describe symptoms experienced by day of the cycle, where day 1 is the first day of bleeding.
122 We fitted multivariable logistic regression models to explore the association between individual
123 characteristics (age, BMI) and experience of menstrual symptoms. Menstrual symptoms were
124 divided into categories (somatic, gastrointestinal, negative mood, and positive mood) and were

125 considered if any symptom in the category was logged at any point in the cycle. We categorized
126 the age of study subjects into five groups (18-24, 25-29, 30-34, 35-39, and 40-45), where the
127 most represented age category, age 30-34, was used as the reference group. BMI was categorized
128 into four groups (<18.5, 18.5-24.9, 25-29.9, 30+). All models controlled for the total number of
129 symptoms reported. Data were analyzed in Python Jupyter Notebook 6.0.1 and R version 4.2.0.

130 **Results:**

131 A total of 224,676 unique users and 498,126 unique, normal menstrual cycles met inclusion
132 criteria and were included for analysis with a median and interquartile range (IQR) of the cycle
133 length of 2.0 and 1.0, respectively, per individual. The mean age of users was 30.2 ± 5.7 years;
134 users under age 18 or over 45 were excluded from the analysis. Mean BMI, available for 135,979
135 users (60.5% of total users) was 26.0 (13.5 - 58.3) kg/m^2 . Users were included from 222 countries,
136 with 93 countries having at least 100 users. The largest group of users was in the United States
137 ($n=73,015$), followed by Germany ($n=19,956$) and the United Kingdom ($n=17,437$).

138 Of the 498,126 cycles included in this analysis, mean cycle length was 29.1 ± 3.4 days
139 (median 28.8 days), and mean length of bleeding was 4.0 ± 1.2 days (median 4.0 days). Most
140 users recorded a cycle length of 25-30 days (64.1%, $n = 144,148$), followed by cycle length of
141 31-34 days (20.5%, $n=46,072$), 35-40 days (8.0%, $n=17,921$), and 21-24 (7.3 %, $n = 16,535$).
142 Calculated from the predicted day of ovulation, the mean follicular phase length amongst users
143 was 15.6 ± 3.5 days (median 15.0 days), and the mean luteal phase length was 13.5 ± 2.8 days
144 (median 13.4 days).

145 Somatic symptoms were reported most often; 85.3% ($n=498,126$) of cycles reported at
146 least one somatic symptom. Comparatively, gastrointestinal symptoms were reported in 55.8% of

147 cycles (n=278,090), positive mood symptoms were reported in 24.1% (n=119,961) of cycles, and
148 negative mood symptoms were reported in 31.6% (n=157,412). The type and frequency of
149 symptoms are shown in Figure 2. Menstrual cramps, breast tenderness, headache, and fatigue
150 were the most common symptoms reported.

151 Symptoms were next assessed by the menstrual cycle phase. Somatic, gastrointestinal,
152 and negative mood symptoms were most frequent in the late luteal phase and least frequent in the
153 mid-follicular phase (Figure 3). 54.5% of all logged instances of tender breasts occurred during
154 the late luteal phase compared to 2.5% in the mid-follicular phase. Discharge and positive mood
155 symptoms were most common during the fertile window. 68.1% of all logged instances of egg
156 white discharge and 44.5% of all logged instances of high sex drive were during the fertile
157 window.

158 For cycles between 25-30 days in length (n=294,180 cycles), we examined daily
159 symptom logs for the three symptoms with the most variability per category (Figure 4). Overall,
160 most symptoms are reported on day 1 of the cycle (238,391 symptoms logged from 110,206
161 cycles out of 294,180 total cycles); however, the fertile window is where most cycles have at
162 least one symptom logged. Out of 294,180 total cycles, 210,910 cycles had at least one symptom
163 logged during the fertile window, and 146,580 had at least one symptom logged during the
164 bleeding days. The prevalence of somatic, gastrointestinal, and negative mood symptoms are
165 highest on day 1 but decline quickly, reaching their lowest point around day 6 before slowly
166 increasing throughout the rest of the cycle. For positive mood symptoms, the prevalence of
167 energetic mood remains relatively stable throughout the cycle, while happy and high-sex-drive
168 moods increase slowly in the early part of the cycle, peaking around day 13-14 of the cycle and
169 reaching baseline around day 19. Discharge symptoms are rarely logged during the early part of

170 the cycle where bleeding occurs. Egg white discharge increases rapidly between days 6 and 13
171 before decreasing quickly to a low level by day 19.

172 For countries with at least 100 users, the number per country ranged from 104 in
173 Zimbabwe to 73,015 in the United States (Supplemental Table 1). Prevalence of cramps during
174 the last cycle ranged from 4.3% in Vietnam to 23.5% in Iceland (Figure 5). Bloating ranged from
175 1.7% in The Congo to 9.5% in Tunisia. Mood swings ranged from 0.8% in Iceland to 7.6% in
176 Jamaica.

177 Younger users, aged 18-24, were more likely to report positive mood symptoms at any
178 point in the cycle compared to women aged 30-34 (referent group) (OR 1.39, 95%CI: 1.33 -
179 1.46) and were also more likely to experience negative mood symptoms (OR: 1.38, 95%CI: 1.31
180 - 1.44). Younger women were less likely to report any somatic symptoms (OR 0.87, 95%CI: 0.81
181 - 0.93). Gastrointestinal symptoms did not differ between young and referent aged women but
182 were reported more frequently in users aged 40-45 (OR 1.11, 95%CI: 1.04 - 1.19).

183 There was no significant association between BMI and experiencing either a somatic or
184 negative mood symptom at any point across the cycle whilst controlling for age and total number
185 of symptoms logged.

186 **Discussion:**

187 In this study, we report the frequency of somatic, gastrointestinal, mood, and discharge
188 symptoms experienced throughout the menstrual cycle by a cohort of global, ovulating period
189 tracking app users. Notably, most users were aged 30-34 and located in Europe and the United
190 States. Our results build on prior work evaluating the menstrual cycle characteristics of women

191 using period tracking apps. The median cycle length, 28.7 days in our study, is consistent with
192 previous studies and period tracking app data^{17,20-24}.

193 Somatic symptoms were reported most frequently, with cramps being the most reported
194 symptom. Somatic, gastrointestinal, and negative mood symptoms were more common in the
195 late luteal phase than in the rest of the cycle and reached a nadir in the mid-follicular phase
196 between bleeding and the fertile window/ovulation. The hormonal changes observed in the luteal
197 phase may explain these findings. There is a direct correlation between the rapid rise of
198 progesterone, the dominant sex hormone in the luteal phase, and the abrupt increase in somatic
199 symptoms. Progesterone has been shown to influence breast changes and associated breast
200 tenderness in the luteal phase²⁵. By thermoregulatory actions, progesterone has also been shown
201 to impact circadian rhythms leading to decreased REM sleep in the luteal phase and thus a
202 reported increase in fatigue²⁶. However, progesterone levels fall in the week prior to
203 menstruation while somatic symptoms continue to increase. Symptoms in the late luteal phase
204 reflect the effect of decreasing systemic sex steroid hormones. Pain disorders, such as migraines
205 and non-migraine headaches, have been shown to increase in the late luteal phase when estradiol
206 levels are lowest²⁷⁻²⁹, in line with our findings of headaches being most reported in this phase.
207 These effects are modulated by estrogen effects on central pain processing networks and cerebral
208 vasculature²⁸. Conversely, decreasing progesterone levels and the resultant increase in available
209 androgen receptors may explain the increase in acne reported in the late luteal phase³⁰.

210 Gastrointestinal symptoms that increase throughout the luteal phase likely reflect multiple
211 mechanisms³. First, the effect of progesterone on serotonergic activity in both the central nervous
212 system and the GI tract slows gastrointestinal motility leading to constipation in the early luteal
213 phase³¹. Second, increasing prostaglandin levels in the late luteal phase lead to stimulation of

214 smooth muscle contractions – leading to both uterine cramping and increased gastrointestinal
215 motility and associated diarrhea³².

216 The effect of the menstrual cycle on mental health has been well studied, and
217 premenstrual mood disorders are well classified, with over 300 subtypes reported. Mood changes
218 in the luteal phase affect 50-80% of reproductive-aged women, although 3-8% of individuals
219 have such severe symptoms with associated functional impairments that they meet diagnostic
220 criteria in the DSM-IV³³. Our study confirmed an increase in negative mood symptoms
221 throughout the luteal phase, possibly reflecting known alterations in sex steroids and the
222 following neurotransmitters: serotonin, noradrenaline, and gamma-aminobutyric acid
223 (GABA)^{33,34}. Negative mood symptoms decreased throughout the follicular phase, with a
224 corresponding increase in positive mood symptoms that reached peak levels in the late follicular
225 phase. Positive mood symptom frequency in the follicular phase is consistent with prior studies
226 reporting individual well-being to be highest at this time in the cycle^{35,36}. Recent work utilizing
227 functional magnetic resonance imaging (fMRI) has added to our understanding. Sex hormones
228 appear to impact communication between brain regions, in addition to their known impact on
229 neurotransmitter secretion³⁷. This impacts cognition and emotional processing, such that estrogen
230 seems to decrease reaction to negative stimuli while progesterone seems to increase emotional
231 reactions to negative stimuli³⁸.

232 Different menstrual symptom patterns by age have been described³⁹. While we found
233 occurrence of somatic symptoms at any time during the cycle was lowest in the youngest and
234 oldest age groups, premenstrual symptom research has found premenstrual cramps and
235 abdominal pain decrease with age while other somatic premenstrual symptoms (e.g. back pain,
236 abdominal bloating, breast tenderness) are lower in the youngest and oldest groups. The

237 relationship between BMI and menstrual symptoms in the literature is mixed. Some research
238 suggests obesity may be a risk factor for premenstrual syndrome^{40,41} while other research failed
239 to find an association between BMI and premenstrual symptoms⁴². Similarly, we found no
240 relationship between BMI and somatic or negative mood symptoms.

241 We found small geographic differences in user-reported symptoms during the
242 menstrual cycle. This may reflect the impact of knowledge or socio-cultural constructs, which
243 impact individual perceptions of symptoms and their menstrual experience⁴⁴. Historically,
244 menstruation has been mainly described negatively. Previous work has shown an association
245 between early menstrual/menarchal experiences and current menstrual experience, body
246 perception, and overall health⁴⁵⁻⁴⁸. However, other studies examining symptom experience
247 across broad geographic regions have not found regional differences in symptoms³⁹.

248 The strength of this study lies in the number of unique users and in a large amount of
249 user-reported data from a global population. However, this study is not without limitations.
250 Specifically, this study is subject to selection bias as not all menstruating individuals choose to
251 use period tracking apps. Demographic and other individual characteristic data were not
252 collected, including user-reported race and ethnicity, which may be important mediators of
253 menstrual symptom characteristics and experiences that may impact our results. We included
254 only ovulatory cycles with ovulation confirmed by self-ovulation test to more accurately divide
255 the cycle into phases. Users logging ovulation tests likely have a goal of conception and may
256 thus have a different experience of menstrual symptoms and a difference in the tendency of
257 logging symptoms. Additionally, irregular and non-ovulatory cycles are not represented in this
258 analysis, and results are not generalizable to these populations. Although this study represents a
259 global menstruating population, many countries remain un- or underrepresented, presenting an

260 opportunity for future research. Other limitations include the use of self-reported symptom
261 tracking data. Users log symptoms through the app but may not log symptoms consistently
262 throughout the cycle (e.g. potentially more likely to log symptoms when logging other events
263 such as ovulation or period) and may not log all symptoms experienced. Users also may be more
264 likely to log symptoms that appear at the top and front of the app over symptoms that appear
265 lower down or require scrolling to see, decreasing the representativeness of symptoms recorded
266 and limiting comparability with other methods of symptom data collection.

267 In conclusion, our study presents an expanded understanding of symptoms experienced
268 during the menstrual cycle. These findings reflect the value of population-level menstrual cycle
269 data, which can help inform individual patients and clinicians while strengthening research
270 efforts and calls for advocacy for Women's Health.

271

272 References


- 273 1. Lacovides S, Avidon I, Baker FC. What we know about primary dysmenorrhea today: a
274 critical review. *Hum Reprod Update*. 2015;21(6):762-778. doi:10.1093/humupd/dmv039
- 275 2. Moore J, Barlow D, Jewell D, Kennedy S. Do gastrointestinal symptoms vary with the
276 menstrual cycle? *Br J Obstet Gynaecol*. 1998;105(12):1322-1325. doi:10.1111/j.1471-
277 0528.1998.tb10014.x
- 278 3. Judkins TC, Dennis-Wall JC, Sims SM, Colee J, Langkamp-Henken B. Stool frequency and
279 form and gastrointestinal symptoms differ by day of the menstrual cycle in healthy adult
280 women taking oral contraceptives: a prospective observational study. *BMC Womens Health*.
281 2020;20(1):136. doi:10.1186/s12905-020-01000-x
- 282 4. Lete I, Häusler G, Pintiaux A, et al. The inconvenience due to women's monthly bleeding
283 (ISY) survey: a study of premenstrual symptoms among 5728 women in Europe. *Eur J
284 Contracept Reprod Health Care Off J Eur Soc Contracept*. 2017;22(5):354-359.
285 doi:10.1080/13625187.2017.1400001
- 286 5. Bernstein MT, Graff LA, Avery L, Palatnick C, Parnerowski K, Targownik LE.
287 Gastrointestinal symptoms before and during menses in healthy women. *BMC Womens
288 Health*. 2014;14:14. doi:10.1186/1472-6874-14-14
- 289 6. Chen CX, Draucker CB, Carpenter JS. What women say about their dysmenorrhea: a
290 qualitative thematic analysis. *BMC Womens Health*. 2018;18(1):47. doi:10.1186/s12905-018-
291 0538-8
- 292 7. Chen CX, Kwekkeboom KL, Ward SE. Beliefs About Dysmenorrhea and Their Relationship
293 to Self-Management. *Res Nurs Health*. 2016;39(4):263-276. doi:10.1002/nur.21726
- 294 8. Ramos-Pichardo JD, Ortega-Galán ÁM, Iglesias-López MT, Abreu-Sánchez A, Fernández-
295 Martínez E. Why Do Some Spanish Nursing Students with Menstrual Pain Fail to Consult
296 Healthcare Professionals? *Int J Environ Res Public Health*. 2020;17(21):E8173.
297 doi:10.3390/ijerph17218173
- 298 9. Schoep ME, Adang EMM, Maas JWM, De Bie B, Aarts JWM, Nieboer TE. Productivity loss
299 due to menstruation-related symptoms: a nationwide cross-sectional survey among 32 748
300 women. *BMJ Open*. 2019;9(6):e026186. doi:10.1136/bmjopen-2018-026186
- 301 10. Critchley HOD, Babayev E, Bulun SE, et al. Menstruation: science and society. *Am J
302 Obstet Gynecol*. 2020;223(5):624-664. doi:10.1016/j.ajog.2020.06.004
- 303 11. Matteson KA, Zaluski KM. Menstrual Health as a Part of Preventive Health Care. *Obstet
304 Gynecol Clin North Am*. 2019;46(3):441-453. doi:10.1016/j.ogc.2019.04.004
- 305 12. Chen CX, Shieh C, Draucker CB, Carpenter JS. Reasons women do not seek health care
306 for dysmenorrhea. *J Clin Nurs*. 2018;27(1-2):e301-e308. doi:10.1111/jocn.13946
- 307 13. Tan DA, Haththotuwa R, Fraser IS. Cultural aspects and mythologies surrounding
308 menstruation and abnormal uterine bleeding. *Best Pract Res Clin Obstet Gynaecol*.
309 2017;40:121-133. doi:10.1016/j.bpobgyn.2016.09.015
- 310 14. Symul L, Wac K, Hillard P, Salathé M. Assessment of menstrual health status and
311 evolution through mobile apps for fertility awareness. *NPJ Digit Med*. 2019;2:64.
312 doi:10.1038/s41746-019-0139-4
- 313 15. Mao L, Xi S, Bai W, et al. Menstrual patterns and disorders among Chinese women of
314 reproductive age: A cross-sectional study based on mobile application data. *Medicine
315 (Baltimore)*. 2021;100(16):e25329. doi:10.1097/MD.00000000000025329
- 316 16. Karasneh RA, Al-Azzam SI, Alzoubi KH, Muflih SM, Hawamdeh SS. Smartphone
317 Applications for Period Tracking: Rating and Behavioral Change among Women Users.

- 318 *Obstet Gynecol Int.* 2020;2020:2192387. doi:10.1155/2020/2192387
- 319 17. Bull JR, Rowland SP, Scherwitzl EB, Scherwitzl R, Danielsson KG, Harper J. Real-
320 world menstrual cycle characteristics of more than 600,000 menstrual cycles. *NPJ Digit Med.*
321 2019;2:83. doi:10.1038/s41746-019-0152-7
- 322 18. Mahalanobis P. On the generalised distance in statistics. *Proc Natl Inst Sci India.*
323 1936;2(1):49-55.
- 324 19. Leskovec J, Rajaraman A, Ullman JD. *Mining of Massive Data Sets.* Cambridge
325 University Press; 2020.
- 326 20. Li K, Urteaga I, Wiggins CH, et al. Characterizing physiological and symptomatic
327 variation in menstrual cycles using self-tracked mobile-health data. *NPJ Digit Med.*
328 2020;3:79. doi:10.1038/s41746-020-0269-8
- 329 21. Najmabadi S, Schliep KC, Simonsen SE, Porucznik CA, Egger MJ, Stanford JB.
330 Menstrual bleeding, cycle length, and follicular and luteal phase lengths in women without
331 known subfertility: A pooled analysis of three cohorts. *Paediatr Perinat Epidemiol.*
332 2020;34(3):318-327. doi:10.1111/ppe.12644
- 333 22. Li K, Urteaga I, Shea A, Vitzthum VJ, Wiggins CH, Elhadad N. A predictive model for
334 next cycle start date that accounts for adherence in menstrual self-tracking. *J Am Med Inform*
335 *Assoc JAMIA.* 2021;29(1):3-11. doi:10.1093/jamia/ocab182
- 336 23. Grieger JA, Norman RJ. Menstrual Cycle Length and Patterns in a Global Cohort of
337 Women Using a Mobile Phone App: Retrospective Cohort Study. *J Med Internet Res.*
338 2020;22(6):e17109. doi:10.2196/17109
- 339 24. Broad A, Biswakarma R, Harper JC. A survey of women's experiences of using period
340 tracker applications: Attitudes, ovulation prediction and how the accuracy of the app in
341 predicting period start dates affects their feelings and behaviours. *Womens Health Lond Engl.*
342 2022;18:17455057221095246. doi:10.1177/17455057221095246
- 343 25. Graham JD, Clarke CL. Physiological action of progesterone in target tissues. *Endocr*
344 *Rev.* 1997;18(4):502-519. doi:10.1210/edrv.18.4.0308
- 345 26. Shechter A, Varin F, Boivin DB. Circadian variation of sleep during the follicular and
346 luteal phases of the menstrual cycle. *Sleep.* 2010;33(5):647-656. doi:10.1093/sleep/33.5.647
- 347 27. LeResche L, Mancl L, Sherman JJ, Gandara B, Dworkin SF. Changes in
348 temporomandibular pain and other symptoms across the menstrual cycle. *Pain.*
349 2003;106(3):253-261. doi:10.1016/j.pain.2003.06.001
- 350 28. Sacco S, Ricci S, Degan D, Carolei A. Migraine in women: the role of hormones and
351 their impact on vascular diseases. *J Headache Pain.* 2012;13(3):177-189.
352 doi:10.1007/s10194-012-0424-y
- 353 29. Stening K, Eriksson O, Wahren L, Berg G, Hammar M, Blomqvist A. Pain sensations to
354 the cold pressor test in normally menstruating women: comparison with men and relation to
355 menstrual phase and serum sex steroid levels. *Am J Physiol Regul Integr Comp Physiol.*
356 2007;293(4):R1711-1716. doi:10.1152/ajpregu.00127.2007
- 357 30. Raghunath RS, Venables ZC, Millington GWM. The menstrual cycle and the skin. *Clin*
358 *Exp Dermatol.* 2015;40(2):111-115. doi:10.1111/ced.12588
- 359 31. Xiao ZL, Pricolo V, Biancani P, Behar J. Role of progesterone signaling in the regulation
360 of G-protein levels in female chronic constipation. *Gastroenterology.* 2005;128(3):667-675.
361 doi:10.1053/j.gastro.2004.12.001
- 362 32. Evans J, Salamonsen LA. Inflammation, leukocytes and menstruation. *Rev Endocr Metab*
363 *Disord.* 2012;13(4):277-288. doi:10.1007/s11154-012-9223-7

- 364 33. Ryu A, Kim TH. Premenstrual syndrome: A mini review. *Maturitas*. 2015;82(4):436-
365 440. doi:10.1016/j.maturitas.2015.08.010
- 366 34. Toffol E, Kalleinen N, Urrila AS, et al. The relationship between mood and sleep in
367 different female reproductive states. *BMC Psychiatry*. 2014;14:177. doi:10.1186/1471-244X-
368 14-177
- 369 35. Sanders D, Warner P, Bäckström T, Bancroft J. Mood, sexuality, hormones and the
370 menstrual cycle. I. Changes in mood and physical state: description of subjects and method.
371 *Psychosom Med*. 1983;45(6):487-501. doi:10.1097/00006842-198312000-00003
- 372 36. Meaden PM, Hartlage SA, Cook-Karr J. Timing and severity of symptoms associated
373 with the menstrual cycle in a community-based sample in the Midwestern United States.
374 *Psychiatry Res*. 2005;134(1):27-36. doi:10.1016/j.psychres.2005.01.003
- 375 37. Toffoletto S, Lanzenberger R, Gingnell M, Sundström-Poromaa I, Comasco E. Emotional
376 and cognitive functional imaging of estrogen and progesterone effects in the female human
377 brain: a systematic review. *Psychoneuroendocrinology*. 2014;50:28-52.
378 doi:10.1016/j.psyneuen.2014.07.025
- 379 38. Sakaki M, Mather M. How reward and emotional stimuli induce different reactions
380 across the menstrual cycle. *Soc Personal Psychol Compass*. 2012;6(1):1-17.
381 doi:10.1111/j.1751-9004.2011.00415.x
- 382 39. Dennerstein L, Lehert P, Heinemann K. Global epidemiological study of variation of
383 premenstrual symptoms with age and sociodemographic factors. *Menopause Int*.
384 2011;17(3):96-101. doi:10.1258/mi.2011.011028
- 385 40. Bertone-Johnson ER, Hankinson SE, Willett WC, Johnson SR, Manson JE. Adiposity
386 and the Development of Premenstrual Syndrome. *J Womens Health*. 2010;19(11):1955-1962.
387 doi:10.1089/jwh.2010.2128
- 388 41. Masho SW, Adera T, South-Paul J. Obesity as a risk factor for premenstrual syndrome. *J*
389 *Psychosom Obstet Gynaecol*. 2005;26(1):33-39. doi:10.1080/01443610400023049
- 390 42. Sadler C, Smith H, Hammond J, et al. Lifestyle factors, hormonal contraceptives and
391 premenstrual symptoms: The UK Southampton Women's Survey. *J Womens Health* 2002.
392 2010;19(3):391-396. doi:10.1089/jwh.2008.1210
- 393 43. Kiesner J, Pastore M. Day-to-day co-variations of psychological and physical symptoms
394 of the menstrual cycle: insights to individual differences in steroid reactivity.
395 *Psychoneuroendocrinology*. 2010;35(3):350-363. doi:10.1016/j.psyneuen.2009.07.011
- 396 44. Marván ML, Escobedo C. Premenstrual symptomatology: role of prior knowledge about
397 premenstrual syndrome. *Psychosom Med*. 1999;61(2):163-167. doi:10.1097/00006842-
398 199903000-00007
- 399 45. McPherson ME, Korfine L. Menstruation across time: menarche, menstrual attitudes,
400 experiences, and behaviors. *Womens Health Issues Off Publ Jacobs Inst Womens Health*.
401 2004;14(6):193-200. doi:10.1016/j.whi.2004.08.006
- 402 46. Stubbs ML. Cultural perceptions and practices around menarche and adolescent
403 menstruation in the United States. *Ann N Y Acad Sci*. 2008;1135:58-66.
404 doi:10.1196/annals.1429.008
- 405 47. Padmanabhanunni A, Jaffer L, Steenkamp J. Menstruation experiences of South African
406 women belonging to the ama-Xhosa ethnic group. *Cult Health Sex*. 2018;20(6):704-714.
407 doi:10.1080/13691058.2017.1371335
- 408 48. Barrington DJ, Robinson HJ, Wilson E, Hennegan J. Experiences of menstruation in high
409 income countries: A systematic review, qualitative evidence synthesis and comparison to low-

410 and middle-income countries. *PloS One*. 2021;16(7):e0255001.
411 doi:10.1371/journal.pone.0255001
412

413 *Figure 1. An illustrative description of cycle phases*



414

415

416 Legend: Multiple sub-phases in the follicular phase of the menstrual cycle were used to more
417 deeply assess symptoms during the menstrual cycle. The luteal phase was divided into two
418 halves for the purpose of symptom report.


419

420

421

422

423 *Figure 2: Number of unique cycles with experience of specific symptoms (n=498,126 cycles) and*
424 *percent of cycles with each symptom*



425


426 Figure Legend: The number of unique cycles containing mood and somatic symptoms, group by
427 type, are presented with a count of individual symptoms included in each category.

428

429

430

431 *Figure 3: Symptom distribution by phase (n= 8,682,238 logged symptoms)*




432

433 Figure Legend: Symptom distribution per phase of the menstrual cycle is shown. Y-axis

434 represents the percentage of symptom occurrence and type of symptom reported.


435
436 *Figure 4: Daily logs of the three symptoms within each category with the highest variability*
437 *across the cycle for cycles between 25-30 days (n=294,180 cycles)*



438

439

440 *Figure 5 Proportion of users by country with experience of the top symptoms in each category during their last cycle (n=224,670*
 441 *users with available country information)*



442

443 *Figure Legend: The prevalence of most frequently reported symptoms (Figure 5A cramps, Figure 5B bloating, Figure 5C mood*
 444 *swings) is shown by geographic distribution of app users.*

445 Supplementary tables

446

447 *Supplementary table 1. Users per country (in countries with at least 100 users), and prevalence*

448 *of cramps, bloating, and mood swings.*

| Country | Number of users | Cramps | Bloating | Mood swings |
|--------------------|------------------------|---------------|-----------------|--------------------|
| Algeria | 289 | 14.9 | 3.5 | 3.8 |
| Angola | 114 | 18.4 | 5.3 | 2.6 |
| Argentina | 776 | 12.8 | 8.9 | 4.1 |
| Australia | 7650 | 17.4 | 5.4 | 2.9 |
| Austria | 1669 | 17.9 | 5.0 | 3.4 |
| Belarus | 1021 | 21.5 | 4.3 | 4.2 |
| Belgium | 1356 | 19.1 | 4.8 | 3.3 |
| Brazil | 9804 | 15.5 | 4.3 | 4.9 |
| Bulgaria | 150 | 16.7 | 4.0 | 2.0 |
| Cameroon | 304 | 10.2 | 2.3 | 2.3 |
| Canada | 8802 | 18.3 | 5.1 | 2.3 |
| Chile | 390 | 13.6 | 8.7 | 2.8 |
| China | 568 | 10.9 | 4.6 | 5.5 |
| Colombia | 578 | 11.6 | 5.5 | 3.6 |
| Congo | 180 | 10.6 | 1.7 | 3.3 |
| Costa Rica | 112 | 10.7 | 4.5 | 7.1 |
| Côte d'Ivoire | 295 | 11.9 | 3.4 | 2.4 |
| Croatia | 173 | 16.2 | 2.3 | 2.3 |
| Czech Republic | 425 | 18.1 | 4.2 | 3.3 |
| Denmark | 1038 | 17.5 | 5.7 | 2.9 |
| Dominican Republic | 627 | 12.9 | 3.5 | 3.2 |
| Ecuador | 263 | 12.2 | 6.5 | 4.9 |
| Egypt | 191 | 11.5 | 4.7 | 5.8 |
| Estonia | 220 | 16.4 | 5.0 | 4.5 |

| | | | | |
|-------------|-------|------|-----|-----|
| Finland | 1663 | 18.9 | 4.9 | 1.9 |
| France | 8892 | 17.2 | 4.1 | 2.0 |
| Germany | 19956 | 17.4 | 4.9 | 2.9 |
| Ghana | 799 | 15.9 | 3.1 | 3.3 |
| Greece | 248 | 16.9 | 4.4 | 2.4 |
| Guadeloupe | 135 | 15.6 | 2.2 | 2.2 |
| Guatemala | 161 | 18.6 | 3.7 | 2.5 |
| Honduras | 128 | 20.3 | 7.0 | 2.3 |
| Hong Kong | 272 | 12.5 | 4.0 | 1.5 |
| Hungary | 220 | 20.9 | 5.0 | 1.8 |
| Iceland | 119 | 23.5 | 5.9 | 0.8 |
| India | 2054 | 15.8 | 4.4 | 4.1 |
| Indonesia | 1112 | 13.5 | 4.1 | 5.3 |
| Ireland | 1262 | 19.7 | 6.0 | 2.6 |
| Israel | 253 | 19.0 | 4.3 | 2.0 |
| Italy | 5739 | 14.4 | 4.0 | 3.6 |
| Jamaica | 367 | 12.0 | 3.8 | 7.6 |
| Japan | 1903 | 12.5 | 2.9 | 3.0 |
| Kazakhstan | 1138 | 16.2 | 5.9 | 5.5 |
| Kenya | 394 | 15.2 | 4.8 | 4.3 |
| Korea | 244 | 9.8 | 5.7 | 2.5 |
| Latvia | 153 | 17.6 | 7.2 | 3.9 |
| Lebanon | 115 | 14.8 | 2.6 | 0.9 |
| Lithuania | 145 | 20.7 | 4.1 | 3.4 |
| Luxembourg | 182 | 15.4 | 7.1 | 3.3 |
| Malaysia | 889 | 14.3 | 5.2 | 2.6 |
| Mauritius | 111 | 14.4 | 6.3 | 6.3 |
| Mexico | 2099 | 14.7 | 5.1 | 3.7 |
| Morocco | 144 | 16.0 | 5.6 | 3.5 |
| Netherlands | 2136 | 18.8 | 5.3 | 2.8 |
| New Zealand | 949 | 18.4 | 4.8 | 2.0 |

| | | | | |
|----------------------|-------|------|-----|-----|
| Nigeria | 1739 | 13.5 | 3.5 | 5.8 |
| Norway | 1396 | 17.0 | 5.8 | 2.8 |
| Pakistan | 188 | 12.2 | 5.3 | 5.9 |
| Panama | 125 | 9.6 | 4.0 | 3.2 |
| Paraguay | 109 | 12.8 | 3.7 | 6.4 |
| Peru | 318 | 11.3 | 5.7 | 1.9 |
| Philippines | 1305 | 14.4 | 3.8 | 4.4 |
| Poland | 4145 | 12.5 | 2.9 | 3.9 |
| Portugal | 935 | 15.1 | 5.1 | 2.1 |
| Puerto Rico | 208 | 17.8 | 6.3 | 2.4 |
| Réunion | 133 | 16.5 | 4.5 | 1.5 |
| Romania | 493 | 18.7 | 6.7 | 2.8 |
| Russian Federation | 10984 | 20.0 | 4.4 | 3.8 |
| Saudi Arabia | 180 | 16.1 | 5.0 | 6.1 |
| Senegal | 123 | 15.4 | 3.3 | 3.3 |
| Serbia | 112 | 12.5 | 8.0 | 4.5 |
| Singapore | 910 | 16.7 | 4.6 | 1.6 |
| Slovakia | 112 | 13.4 | 7.1 | 2.7 |
| Slovenia | 146 | 15.1 | 6.2 | 2.7 |
| South Africa | 1697 | 16.6 | 5.2 | 3.6 |
| Spain | 3871 | 14.6 | 6.0 | 2.4 |
| Sri Lanka | 108 | 13.9 | 2.8 | 1.9 |
| Sweden | 3134 | 17.5 | 4.5 | 3.6 |
| Switzerland | 1526 | 17.4 | 4.1 | 2.2 |
| Taiwan | 408 | 9.8 | 3.7 | 2.2 |
| Thailand | 1018 | 9.5 | 1.9 | 3.7 |
| Trinidad and Tobago | 232 | 17.2 | 4.3 | 3.4 |
| Tunisia | 137 | 8.8 | 9.5 | 4.4 |
| Turkey | 654 | 13.8 | 6.7 | 3.4 |
| Ukraine | 1827 | 19.4 | 3.2 | 4.2 |
| United Arab Emirates | 450 | 15.8 | 5.8 | 1.8 |

| | | | | |
|----------------|-------|------|-----|-----|
| United Kingdom | 17437 | 18.2 | 5.2 | 2.6 |
| United States | 73015 | 19.0 | 5.3 | 2.6 |
| Uzbekistan | 137 | 9.5 | 5.8 | 3.6 |
| Venezuela | 293 | 9.9 | 4.1 | 4.1 |
| Viet Nam | 282 | 4.3 | 2.5 | 1.8 |
| Zambia | 163 | 13.5 | 6.7 | 3.1 |
| Zimbabwe | 104 | 14.4 | 4.8 | 1.9 |